Your browser is no longer supported. Please, upgrade your browser.
REPL Replimune Group, Inc. weekly Stock Chart
REPL [NASD]
Replimune Group, Inc.
Index- P/E- EPS (ttm)-1.33 Insider Own13.00% Shs Outstand38.09M Perf Week10.03%
Market Cap375.95M Forward P/E- EPS next Y-1.87 Insider Trans33.67% Shs Float30.65M Perf Month-29.70%
Income-43.50M PEG- EPS next Q-0.45 Inst Own74.70% Short Float2.24% Perf Quarter-38.16%
Sales- P/S- EPS this Y-108.00% Inst Trans16.46% Short Ratio6.35 Perf Half Y-29.30%
Book/sh5.66 P/B1.74 EPS next Y-8.10% ROA-24.90% Target Price28.29 Perf Year-32.95%
Cash/sh4.75 P/C2.08 EPS next 5Y- ROE-29.70% 52W Range8.58 - 19.66 Perf YTD-31.22%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-49.80% Beta-
Dividend %- Quick Ratio13.40 Sales past 5Y- Gross Margin- 52W Low15.03% ATR1.48
Employees67 Current Ratio13.40 Sales Q/Q- Oper. Margin- RSI (14)38.83 Volatility13.10% 13.55%
OptionableNo Debt/Eq0.19 EPS Q/Q-91.00% Profit Margin- Rel Volume0.55 Prev Close10.69
ShortableYes LT Debt/Eq0.18 EarningsFeb 13 Payout- Avg Volume107.84K Price9.87
Recom1.70 SMA20-16.06% SMA50-33.96% SMA200-28.86% Volume59,756 Change-7.67%
Sep-04-19Initiated ROTH Capital Buy $20
Jul-23-19Initiated Chardan Capital Markets Buy $28
Jul-12-19Upgrade JP Morgan Neutral → Overweight $27 → $26
Jul-08-19Initiated H.C. Wainwright Buy $26
Apr-25-19Initiated Wedbush Outperform $24
Jan-23-19Downgrade JP Morgan Overweight → Neutral
Aug-14-18Initiated Leerink Partners Outperform $25
Aug-14-18Initiated JP Morgan Overweight $26
Feb-13-20 07:00AM  Replimune Reports Third Fiscal Quarter Financial Results and Provides Corporate Update GlobeNewswire
Feb-06-20 08:00AM  Replimune to Present at Two Upcoming Investor Conferences GlobeNewswire -5.08%
Jan-13-20 07:00AM  Replimune Provides 2019 Year End Corporate Update and Reviews Expected 2020 Milestones GlobeNewswire
Jan-09-20 07:00AM  Replimune Announces the Evolution of its Management Team as it Advances Through Later Stage Clinical Development and Prepares for Commercialization GlobeNewswire
Jan-07-20 08:00AM  Replimune to Present at the 38th Annual J.P.Morgan Healthcare Conference GlobeNewswire
Dec-23-19 02:56PM  Replimune Group, Inc. (NASDAQ:REPL): Are Hedge Funds Right About This Stock? Insider Monkey
Dec-09-19 08:00AM  Replimune Strengthens Executive Team with the Appointment of Jean Franchi as Chief Financial Officer GlobeNewswire
Nov-26-19 08:00AM  Replimune to Present at the Piper Jaffray 31st Annual Healthcare Conference GlobeNewswire
Nov-22-19 12:13PM  Largest Insider Trades of the Week GuruFocus.com
Nov-14-19 06:22AM  Replimune Announces Pricing of Public Offering GlobeNewswire
Nov-12-19 04:06PM  Replimune Announces Proposed Public Offering GlobeNewswire
Nov-11-19 08:00AM  Replimune Reports Second Fiscal Quarter Financial Results and Provides Corporate Update GlobeNewswire
Nov-08-19 07:30AM  Replimune Presents Initial Clinical Data with RP1 that Strongly Supports Expansion of Clinical Programs in Melanoma and Cutaneous Squamous Cell Carcinoma (CSCC) GlobeNewswire
Oct-31-19 04:00PM  Replimune to Host Investor Event at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) GlobeNewswire
02:19PM  Is Replimune Group, Inc. (REPL) A Good Stock To Buy? Insider Monkey
Oct-24-19 08:00AM  Replimune Announces First Patient Enrolled in Phase 1 Clinical Trial of RP2 Alone and in Combination with Opdivo® in Advanced Cancer Patients GlobeNewswire
Oct-15-19 07:00AM  Replimune Provides Update on RP1 Clinical Development Program in Cutaneous Squamous Cell Carcinoma GlobeNewswire +15.02%
Oct-02-19 08:00AM  Replimune Announces Presentation at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting GlobeNewswire -5.77%
Oct-01-19 08:00AM  Replimune to Present at Chardans 3rd Annual Genetic Medicines Conference GlobeNewswire -5.25%
Sep-13-19 04:39AM  2 Downtrodden Small Biotechs That Are Showing Signs of Life TheStreet.com
Aug-14-19 08:00AM  Replimune Reports First Fiscal Quarter Financial Results and Provides Corporate Update GlobeNewswire
Aug-06-19 08:00AM  Replimune to Present at 2019 Wedbush PacGrow Healthcare Conference GlobeNewswire -5.53%
Jul-19-19 09:16AM  Imagine Owning Replimune Group (NASDAQ:REPL) And Wondering If The 17% Share Price Slide Is Justified Simply Wall St.
Jun-28-19 08:00AM  Replimune Reports Fourth Fiscal Quarter and Year 2019 Financial Results and Provides Corporate Update GlobeNewswire +6.15%
Jun-01-19 09:00AM  Replimune Announces Initiation of the Phase 2 Portion of its Ongoing Phase 1/2 Clinical Trial of RP1 as Monotherapy and in Combination with Nivolumab GlobeNewswire
May-30-19 08:00AM  Replimune to Present at Upcoming Investor Conferences GlobeNewswire
May-16-19 07:00AM  Replimune Announces Poster Presentation at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting GlobeNewswire +5.80%
Apr-25-19 02:23PM  Replimune's Lead Asset Likely To Clear Regulatory Hurdle, Wedbush Says In Bullish Initiation Benzinga +6.65%
Apr-01-19 07:00AM  Replimune Announces Presentation at the American Association for Cancer Research Annual Meeting 2019 GlobeNewswire
Feb-14-19 08:00AM  Replimune Reports Financial Results for the Third Fiscal Quarter, Ended December 31, and Provides Development and Corporate Update GlobeNewswire
Feb-07-19 08:00AM  Replimune to Present at Two Upcoming Investor Conferences GlobeNewswire
Jan-04-19 12:33PM  How Much Are Replimune Group, Inc. (NASDAQ:REPL) Insiders Spending On Buying Shares? Simply Wall St.
Jan-03-19 08:00AM  Replimune Highlights Company Progress and Expected 2019 Milestones Ahead of Presentation at the 37th Annual JPMorgan Healthcare Conference GlobeNewswire
Dec-20-18 08:00AM  Replimune to Present at the 37th Annual J.P.Morgan Healthcare Conference GlobeNewswire
Dec-08-18 06:19PM  RA Capital Was Wrong about Achillion Pharmaceuticals, Inc. (ACHN): Is it Time To Buy? Insider Monkey
Dec-05-18 08:00AM  Replimune to Present at the BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference GlobeNewswire
Nov-14-18 08:38AM  Bain Capital Life Sciences Investors, LLC Buys Replimune Group Inc GuruFocus.com
08:00AM  Replimune Reports Financial Results for the Second Fiscal Quarter, Ended September 30, and Provides Development and Corporate Update GlobeNewswire
Sep-26-18 08:00AM  Replimune to Present at the Leerink Partners Roundtable Series: Rare Disease & Oncology GlobeNewswire
Sep-06-18 04:01PM  Replimune Announces FDA Acceptance of Investigational New Drug Application for its Lead Oncolytic Immunotherapy Candidate, RP1 GlobeNewswire
Aug-30-18 08:00AM  Replimune Reports Financial Results for the First Fiscal Quarter, Ended June 30, and Provides Development and Corporate Update GlobeNewswire -9.20%
Aug-14-18 02:49PM  BMO Sees A Low-Risk Biotech Buy In Replimune Benzinga
Jul-24-18 07:44AM  [$$] Gormley's Take: Public Markets' Embrace of Health Care Extends Beyond Biotech The Wall Street Journal
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors. It is also developing RP2, which is in Preclinical trials to express an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Preclinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Coffin RobertPres & Chief Res & Dev OfficerFeb 20Sale17.0424,250413,2202,193,868Feb 24 04:02 PM
Coffin RobertPres & Chief Res & Dev OfficerFeb 12Sale17.0448,500826,1982,218,118Feb 14 04:00 PM
Esposito PamelaChief Business OfficerDec 20Option Exercise1.7525,70044,975112,700Dec 23 04:32 PM
Kaufman HowardChief Medical OfficerNov 26Option Exercise3.3058,067191,62158,067Dec 19 04:02 PM
Rhodes Jason PDirectorNov 18Buy13.611,100,00014,971,0001,100,000Nov 20 05:50 PM
Omega Fund IV, L.P.10% OwnerNov 18Buy13.61220,0002,994,2005,328,939Nov 20 12:36 PM